Ocera Therapeutics, Inc. (Nasdaq: OCRX) 16.3% LOWER; announced preliminary topline results from a Phase 2a investigator-sponsored study evaluating the company's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE